BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Triple-negative breast cancer (TNBC) has poor prognostic outcome compared with other types of breast cancer. The molecular and cellular mechanisms underlying TNBC pathology are not fully understood. Here, we report that the transcription factor BCL11A is overexpressed in TNBC including basal-like breast cancer (BLBC) and that its genomic locus is amplified in up to 38% of BLBC tumours. Exogenous BCL11A overexpression promotes tumour formation, whereas its knockdown in TNBC cell lines suppresses their tumourigenic potential in xenograft models. In the DMBA-induced tumour model, Bcl11a deletion substantially decreases tumour formation, even in p53-null cells and inactivation of Bcl11a in established tumours causes their regression. At the cellular level, Bcl11a deletion causes a reduction in the number of mammary epithelial stem and progenitor cells. Thus, BCL11A has an important role in TNBC and normal mammary epithelial cells. This study highlights the importance of further investigation of BCL11A in TNBC-targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · cited 1×
“At the molecular level, several distinct subtypes of breast cancer have been identified based on gene expression profiling 3,5,6 .”
Self-citationGeneration of a functional mammary gland from a single stem cell
Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M.-L., Wu, L., Lindeman, G. J., & Visvader, J. E. (2006) · Nature · doi:10.1038/nature04372 · Cited by 2,005 · cited 1×
“7b). qRT-PCR analysis of RNA samples from several mammary epithelial compartments 32,33 detected higher levels of Bcl11a expression in the luminal progenitors (CD49b + /CD24 hi ), the basal cells (CD49F hi /CD24 + ) and the mammary stem cell (MaSC) (CD49F hi /CD24 med )-enriched population (Fig.”
Self-citationThe clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 1×
“In addition, cancer sequencing studies have identified mutations of p53, PTEN and BRCA1 in TNBC 1,4,8,9 .”
Self-citationkConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492 · cited 1×
“Importantly, given the recent implication of luminal progenitors as the “cell of origin” of BLBC 37,38 , it will be important to ascertain if Bcl11a upregulation in luminal progenitor cells is one of the earliest steps in TNBC development.”
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878
Distinct stem cells contribute to mammary gland development and maintenance
Van Keymeulen, A., Rocha, A. S., Ousset, M., Beck, B., Bouvencourt, G., Rock, J., Sharma, N., Dekoninck, S., & Blanpain, C. (2011) · Nature · doi:10.1038/nature10573 · Cited by 854
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation
Asselin-Labat, M.-L., Sutherland, K. D., Barker, H., Thomas, R., Shackleton, M., Forrest, N. C., Hartley, L., Robb, L., Grosveld, F. G., van der Wees, J., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1530 · Cited by 840
Hatzis, C. (2011) · JAMA · doi:10.1001/jama.2011.593 · Cited by 699
Cited by
circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression
Chen, B., Wei, W., Huang, X., Xie, X., Kong, Y., Dai, D., Yang, L., Wang, J., Tang, H., & Xie, X. (2018) · Theranostics · doi:10.7150/thno.24106 · Cited by 281
Self-citationApplication of magnetic nanoparticles in nucleic acid detection
Tang, C., He, Z., Liu, H., Xu, Y., Huang, H., Yang, G., Xiao, Z., Li, S., Liu, H., Deng, Y., et al. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00613-6 · Cited by 262
Bauer, D. E., & Orkin, S. H. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.08.001 · Cited by 143
Customizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
Guestini, F., McNamara, K. M., Ishida, T., & Sasano, H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125469 · Cited by 58
“It was found overexpressed in TNBC both at RNA and protein levels in patient samples, in vitro and in vivo [105].”
BackgroundO’Mara, T. A., Spurdle, A. B., Glubb, D. M., & Endometrial Cancer Association Consortium (2019) · Cancers · doi:10.3390/cancers11101440 · Cited by 36
“In some cancers, it has oncogenic effects [38,39], whereas in T cell leukaemia, it may act as a tumor suppressor [37].”
Background
Metadata
- Authors
- Khaled, W. T., Choon Lee, S., Stingl, J., Chen, X., Raza Ali, H., Rueda, O. M., Hadi, F., Wang, J., Yu, Y., Chin, S.-F., Stratton, M., Futreal, A., Jenkins, N. A., Aparicio, S., Copeland, N. G., Watson, C. J., Caldas, C., & Liu, P.
- Venue
- Nature Communications
- Published
- 2015-01-09
- Volume
- 6
- Issue
- 1
- Pages
- 5987-5987
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2077749987
- Cited by
- 155
- References
- 14
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.